Bellerophon Therapeutics announced on July 27 that top-line results from a clinical trial found its investigational cardiac implantable device did not improve outcomes compared with placebo.
CEO Jonathan Peacock said in a news release that the company was “clearly disappointed” with the results of the randomized, double-blind, placebo-controlled study. The company said there were no statistically significant treatment differences or adverse event rates in patients treated with its Bioabsorbable Cardiac Matrix (BCM) or placebo.
The BCM is being tested to prevent heart failure after people have an acute MI. Bellerophon said it would present detailed results of the trial, dubbed PRESERVATION I, on Sept. 1 at the European Society of Cardiology meeting in London.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.